Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cytarabine
  • Fusion Proteins, bcr-abl
  • Interferon-alpha
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Piperazines
  • Pyrimidines

abstract

  • The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine. Patients in the imatinib group with this degree of molecular response had a negligible risk of disease progression during the subsequent 12 months.

publication date

  • October 9, 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa030513

PubMed ID

  • 14534335

Additional Document Info

start page

  • 1423

end page

  • 32

volume

  • 349

number

  • 15